PRF Technologies Ltd 6-K, filed Oct 27, 2021
PRF Technologies Ltd. (PRFX)
6-K
2021-10-27
For: 2021-10-27
View Original
Added on
April 10, 2026
About this 6-K
PRF Technologies Ltd filed this 6-K on October 27, 2021.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of October 2021
Commission File Number: 001-39481
PainReform Ltd.
(Translation of registrant’s name into English)
4 Bruria St. Tel Aviv, 6745442
Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
On October 27, 2021, PainReform Ltd. (the “Company”) announced that it will hold its Annual General Meeting of Shareholders on December 9, 2021 at 11:00 a.m.
(Israel time) at the offices of the Company's attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross., 7 Metsada St., B.S.R Tower 4, 33 Floor, Bnei Brak, Israel. In connection with the meeting, the Company furnishes the following documents:
| 1. |
A copy of the Notice and Proxy Statement with respect to the Company’s Annual General Meeting of Shareholders describing the proposals to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and
various other details related to the meeting, attached hereto as Exhibit 99.1; and
|
| 2. |
A form of Proxy Card whereby holders of ordinary shares of the Company may vote at the meeting without attending in person, attached hereto as Exhibit 99.2.
|
2
Exhibit Index
|
Exhibit No.
|
Description
|
|
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
Date: October 27, 2021
|
|
PAINREFORM LTD.
By: /s/ Ilan Hadar
Ilan Hadar
Chief Executive Officer
|
4
Exhibit 99.1
NOTICE OF
ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE
HELD ON DECEMBER 9, 2021
To the shareholders of PainReform Ltd.:
Notice is hereby given that an Annual General Meeting (the “Meeting”) of the shareholders of PainReform Ltd. (the “Company”) will be
held at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross, at 7 Metsada St., B.S.R Tower 4, Bnei Brak, Israel on December 9, 2021 at 11:00 a.m. (Israel Time),.
Although we intend to hold the Meeting in person, we are sensitive to the public health and travel concerns our
shareholders may have and the protocols that governments may impose. We reserve the right to convert to a virtual only meeting format should meeting in person become unsafe as a result of the COVID-19 pandemic. If we convert to a virtual only online
meeting, we will announce the decision to do so in advance and provide instructions for shareholder participation in the virtual meeting in a Form 6-K filed with the Securities and Exchange Commission and posted on our website www.painreform.com.
The agenda of the Meeting will be as follows:
|
1.
|
To approve the re-election of Prof. Eli Hazum, Dr. Ehud Geller and Efi Cohen-Arazi, to the board of directors of the Company (the “Board of Directors”), each until the
next annual general meeting of shareholders (a separate vote for each director will be taken);.
|
|
2.
|
To appoint Kesselman & Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as the Company’s independent auditors for the fiscal year ending
December 31, 2021, instead of Brightman Almagor Zohar & Co., Certified Public Accountants, a firm in the Deloitte Global Network.
|
|
3.
|
To increase the Company’s authorized share capital by NIS 3,000,000, such that following the increase, the authorized share capital shall equal NIS 8,000,000 divided into 26,666,666 ordinary shares, par value
NIS 0.03 each, and to amend the Company’s articles of association accordingly.
|
Only shareholders at the close of business on November 2, 2021 shall be entitled to notice of, and to vote at, the Meeting and any
adjournment or postponement thereof. You are cordially invited to attend the Meeting in person.
If you are unable to attend the Meeting in person, you are requested to complete, date and sign the enclosed proxy and to return it
promptly in the pre-addressed envelope provided. Shareholders who attend the Meeting may revoke their proxies and vote their shares in person.
|
|
By Order of the Board of Directors
/s/ Ilan Hadar
Ilan Hadar, Chief Executive Officer
October 27, 2021
|
4 Bruria St. Tel Aviv, 6745442
PROXY STATEMENT
FOR ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE
HELD ON DECEMBER 9, 2021
This Proxy Statement is furnished to our holders of ordinary shares, par value NIS 0.03 per share, in connection with Annual General
Meeting of Shareholders, to be held on December 9, 2021 at 11:00 a.m. Israel time at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross., at 7 Metsada St., B.S.R Tower 4, Bnei Brak, Israel, or at any
adjournments thereof.
Although we intend to hold the Meeting in person, we are sensitive to the public health and travel concerns our
shareholders may have and the protocols that governments may impose. We reserve the right to convert to a virtual only meeting format should meeting in person become unsafe as a result of the COVID-19 pandemic. If we convert to a virtual only online
meeting, we will announce the decision to do so in advance and provide instructions for shareholder participation in the virtual meeting in a Form 6-K filed with the Securities and Exchange Commission (the “SEC”).
Throughout this Proxy Statement, we use terms such as “PainReform”, “we”, “us”, “our” and the “Company” to refer to PainReform Ltd. and
terms such as “you” and “your” to refer to our shareholders.
Agenda Items
The agenda of the annual meeting will be as follows:
|
1.
|
To re-elect Prof. Eli Hazum to the board of directors of the Company (the “Board of Directors”), for a term expiring at our next annual general meeting of shareholders.
|
|
2.
|
To re-elect Dr. Ehud Geller to our Board of Directors for a term expiring at our next annual general meeting of shareholders.
|
|
3.
|
To re-elect Efi Cohen-Arazi to our Board of Directors for a term expiring at our next annual general meeting of shareholders.
|
|
4.
|
To appoint Kesselman & Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as the Company’s independent auditors for the fiscal year ending
December 31, 2021, instead of Brightman Almagor Zohar & Co., Certified Public Accountants, a firm in the Deloitte Global Network, and to authorize the Board of Directors, upon the recommendation of the Company’s audit committee (the
“Audit Committee”), to determine the auditors’ remuneration to be fixed in accordance with the volume and nature of their services to the Company for such fiscal year.
|
|
5.
|
To increase our authorized share capital by NIS 3,000,000, such that following the increase, the authorized share capital shall equal NIS 8,000,000 divided into 26,666,666 ordinary shares, par value NIS 0.03
each, and to amend our articles of association accordingly.
|
We currently are unaware of any other matters that may be raised at the Meeting. Should any other matters be properly raised at the
Meeting, the persons designated as proxies shall vote according to their own judgment on those matters.
Board Recommendation
Our Board of Directors unanimously recommends that you vote “FOR” all items.
Who Can Vote
Only the holders of record of ordinary shares (“Ordinary Shares”) of the Company as at the close of business on November 2, 2021, (the
“Record Date”) shall be entitled to receive notice of and attend the Meeting and any adjournment thereof. You are also entitled to notice of the Meeting and to vote at the Meeting if you held Ordinary Shares through a bank, broker or other nominee
that is one of our shareholders of record at the close of business on November 2, 2021, or which appeared in the participant listing of a securities depository on that date.
Quorum
A quorum shall be the presence of at least two (2) shareholders who hold at least twenty five percent (25%) of the voting rights
(including through a proxy or voting instrument) within one half hour from the time the meeting was designated to start. If within half an hour from the time designated for the Meeting a quorum is not present, the Meeting will stand adjourned to the
same day in the following week, at the same time and place. If a quorum is not present at the adjourned meeting within half hour from the time designated for its start, the meeting shall take place with any number of participants. This notice will
serve as notice of such reconvened meeting if no quorum is present at the original date and time and no further notice of the reconvened meeting will be given to shareholders.
On all matters considered at the Meeting, abstentions and broker non-votes will not be treated as either a vote “for” or “against” the
matter, although they will be counted to determine if a quorum is present. Broker non-votes occur when brokers that hold their customers’ shares in street name sign and submit proxies for such shares and vote such shares on some matters but not on
others. This occurs when brokers have not received any instructions from their customers, in which case the brokers, as the holders of record, are permitted to vote on “routine” matters, but not on non-routine matters.
Unsigned or unreturned proxies, including those not returned by banks, brokers, or other record holders, will not be counted for quorum or voting purposes.
Voting Required for Approval of the Proposals
Each Ordinary Share issued and outstanding as of the close of business on the Record Date is entitled to one vote at the Meeting. As of
the close of business on October 26, 2021, 10,482,056 Ordinary Shares were issued and outstanding.
The affirmative vote of the holders of a majority of the voting power represented and voting on a proposal in person or by proxy is
necessary for the approval of each of the Proposals being presented at the Meeting.
Voting by Holders of Ordinary Shares
Ordinary Shares that are properly voted, for which proxy cards are properly executed and returned within the deadline set forth below,
will be voted at the Meeting in accordance with the directions given. If no specific instructions are given in such proxy cards, the proxy holder will vote in favor of the item(s) set forth in the proxy card. The proxy holder will also vote in the
discretion of such proxy holder on any other matters that may properly come before the Meeting, or at any adjournment thereof. Where any holder of Ordinary Shares affirmatively abstains from voting on any particular resolution, the votes attaching to
such Ordinary Shares will not be included or counted in the determination of the number of Ordinary Shares present and voting for the purposes of determining whether such resolution has been passed (but they will be counted for the purposes of
determining the quorum, as described above).
2
Proxies submitted by registered shareholders and street shareholders (by returning the proxy card) must be received
by us no later than 11:59 p.m., Eastern Time, on December 8, 2021, to ensure your representation at our Meeting.
The manner in which your shares may be voted depends on how your shares are held. If you own shares of record, meaning that your shares are
represented by book entries in your name so that you appear as a shareholder on the records of American Stock Transfer & Trust Company, LLC (“AST”) (i.e., you are a registered shareholder), our stock transfer agent, this proxy statement, the
notice of Meeting and the proxy card will be mailed to you by AST. You may provide voting instructions by returning a proxy card. You also may attend the Meeting and vote in person, subject to our right to convert to a virtual only meeting format. If
you own Ordinary Shares of record and you do not vote by proxy or in person at the Meeting, your shares will not be voted.
If you own shares in street name (i.e., you are a streets shareholder), meaning that your shares are held by a bank, brokerage firm, or
other nominee, you are then considered the “beneficial owner” of shares held in “street name,” and as a result, this proxy statement, the notice of Meeting and the proxy card will be provided to you by your bank, brokerage firm, or other nominee
holding the shares. You may provide voting instructions to them directly by returning a voting instruction form received from that institution. If you own Ordinary Shares in street name and attend the Meeting in person, you must obtain a “legal
proxy” from the bank, brokerage firm, or other nominee that holds your shares in order to vote your shares at the Meeting and present your voting information card and subject to our right to convert to a virtual only meeting format.
Revocability of Proxies
Registered shareholders may revoke their proxy or change voting instructions before shares are voted at the Meeting by submitting a
written notice of revocation to our Chief Executive Officer at ihadar@painreform.com or PainReform Ltd., 4 Bruria St. Tel Aviv, 6745442, or a duly executed proxy bearing a later date (which must be received by us no later than the date set forth
below) or by attending the Meeting and voting in person. A beneficial owner owning Ordinary Shares in street name may revoke or change voting instructions by contacting the bank, brokerage firm, or other nominee holding the shares or by obtaining a
legal proxy from such institution and voting in person at the Meeting. If you are not planning to attend in person, to ensure your representation at our Meeting, revocation of proxies submitted by registered
shareholders and street shareholders (by returning a proxy card) must be received by us no later than 11:59 p.m., Eastern Time, on December 8, 2021.
Position Statement
To the extent you would like to submit a position statement with respect to any of proposals described in this proxy statement pursuant
to the Companies Law, 1999, you may do so by delivery of appropriate notice to the offices of our attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross. (Attention: Ronen Kantor, Adv) located at 7 Metsada St., B.S.R Tower 4, Bnei Brak,
Israel, not later than ten days before the convening of the Meeting (i.e. November 29, 2021). Response of the Board to the position statement may be submitted not later than five days after the deadline for sending the position statement (i.e.
December 4, 2021).
Cost of Soliciting Votes for the Meeting
We will bear the cost of soliciting proxies from our shareholders. Proxies will be solicited by mail and may also be solicited in
person, by telephone or electronic communication, by our directors, officers and employees. We will reimburse brokerage houses and other custodians, nominees and fiduciaries for their expenses in accordance with the regulations of the SEC
concerning the sending of proxies and proxy material to the beneficial owners of our shares.
Availability of Proxy Materials
Copies of the proxy card and voting instruction card, the Notice of the Annual Meeting and this Proxy Statement are available at the
“Investor Information” portion of our website, http://www.painreform.com/. The contents of that website are not a part of this Proxy Statement.
Reporting Requirements
We are subject to the information reporting requirements of the Securities Exchange Act of 1934, as amended, or Exchange Act, applicable
to foreign private issuers. We fulfill these requirements by filing reports with the SEC. Our filings are available to the public on the Commission’s website at http://www.sec.gov.
As a foreign private issuer, we are exempt from the rules under the Securities Exchange Act, or Exchange Act of 1934, as amended, related
to the furnishing and content of proxy statements. The circulation of this notice and proxy statement should not be taken as an admission that we are subject to the proxy rules under the Exchange Act.
3
PROPOSAL 1-3:
RE-ELECTION OF DIRECTORS
Background
At the Meeting, three directors are proposed to be re-elected. Each of the re-elected directors will hold office until the next annual
general meeting of shareholders, unless any office is earlier vacated under any relevant provisions of the articles of association of the Company or applicable laws or regulations. If no directors are appointed at the Meeting, the current directors
shall continue to hold office. The Company is not aware of any reason why any of the nominees, if elected, should not be able to serve as a director.
Each of Prof. Eli Hazum, Dr. Ehud Geller and Efi Cohen-Arazi has indicated to the Company his availability for re-election and has declared that: (i) he has
the required qualifications and ability to devote the time required for its service as a director with respect to the Company’s special needs and its size and specified the said qualifications; and (ii) that the limitations specified in sections 225
through 227 of the Companies Law do not apply to such nominee, all pursuant to section 224B of the Companies Law. Such declarations can be found in the Company’s offices.
The three proposed nominees to serve as directors together with the two external directors will constitute the Board of Directors.
The nominees to serve on the Company’s Board of Directors are presented below and the following information with respect to the nominees
is supplied based upon the information furnished to the Company by the nominees:
Prof. Eli Hazum served as our acting Chief Executive Officer from 2012 to November 2020 and our
Chief Technology Officer since April 2018 and a director of our company since December 2019. He has been a partner and CSO of Medica Venture Partners since 1995. Prior to joining Medica, Prof. Hazum spent five years at Glaxo Inc. as Head of the
Department of Receptor Research and Metabolic Diseases and as a member of the Corporate Committee for New Technology Identification in osteoporosis, worldwide. Mr. Hazum received his Ph.D. degree in the field of hormone biochemistry from the Weizmann
Institute of Science, BSc and MSc degrees in Chemistry from Tel Aviv University and an executive MBA degree from Humberside University in the UK. Mr. Hazum devotes 60% of his time to the company.
Dr. Ehud Geller has been the Chairman of our Board of Directors since November 2008. Since
1995, he has been the General Partner of Medica Venture Partners. Between 1979 and 1985, Dr. Geller was President of the Pharmaceutical Division of Teva Pharmaceutical Industries (NYSE:TEVA) and Executive VP of the Teva Group. At Teva, he led the
acquisition of Ikapharm Ltd. He served as the President and CEO of Interpharm Laboratories, Ltd. from 1985 to 1990. During these years he also served as head of the Israeli Pharmaceutical Manufacturers Association and as a Board Member on the Tel
Aviv Stock Exchange (TASE). Dr. Geller has a B.Sc. degree in Chemical Engineering, an MBA degree from Columbia University/Drexel Institute and a Ph.D. degree in pharmaceutical/chemical engineering from Drexel Institute, Philadelphia. Since 1995, he
has been the General Partner of Medica Venture Partners. Mr. Geller was selected to serve on the board of directors as Chairman due to his significant experience leading and growing companies in the pharmaceutical industry and his significant
leadership experience. His experience leading the company’s management and the depth of his knowledge of our business enable him to provide valuable leadership on complex business matters that we face on an ongoing basis.
Efi Cohen-Arazi was the Co-Founder & CEO of Rainbow Medical, Israel’s leading medical
device innovation house since 2008. From 2004 to 2006 Mr. Cohen Arazi served as the CEO and Co-Founder of IntecPharma Ltd. and as Chairman of CollPlant Ltd. since 2006. Mr. Cohen Arazi served as a board director for numerous biotech/medtech companies
since 2005. Mr. Cohen-Arazi was the Senior VP Head of Operations at Immunex Corporation in Seattle, Washington until 2002 when it was acquired by Amgen where he served as VP and General Manager of the TO site in California. Mr. Cohen Arazi served at
Merck-Serono Group in Switzerland and Israel between 1988 and 2000. Mr. Cohen-Arazi graduated summa cum laude with a M.Sc. degree from the Hebrew University of Jerusalem, Israel.
For information on the compensation terms of the directors, see Item 6B of the 2020 Annual Report. In addition, the directors will
continue to benefit from coverage under the Company’s directors’ and officers’ liability insurance policies and from the letters of indemnification provided to them by the Company.
Proposed Resolution
It is proposed that at the Meeting, the following resolutions be adopted:
“RESOLVED, that the re-election of Prof. Eli Hazum to the Company’s Board of Directors, to serve until our next annual general meeting
of shareholders, as presented to the shareholders, be and the same hereby is, approved.”
“RESOLVED, that the re-election of Dr. Ehud Geller to the Company’s Board of Directors, , to serve until our next annual general meeting
of shareholders, as presented to the shareholders, be and the same hereby is, approved.”
“RESOLVED, that the re-election of Mr. Efi Cohen-Arazi to the Company’s Board of Directors, , to serve until our next annual general
meeting of shareholders, as presented to the shareholders, be and the same hereby is, approved.”
Required Vote
Under the Israeli Companies Law and our articles of association, the affirmative vote of the holders of a majority of the ordinary
shares represented at the annual meeting, in person or by proxy, entitled to vote and voting on the matter, is required to re-elect as directors each of the nominees named above.
Board Recommendation
The Board of Directors recommends a vote “FOR” the re-election of the foregoing director nominees.
4
PROPOSAL 4:
APPOINTMENT OF KESSELMAN & KESSELMAN, CERTIFIED PUBLIC ACCOUNTANTS IN ISRAEL AND A MEMBER OF PRICEWATERHOUSECOOPERS INTERNATIONAL
LIMITED, AS THE COMPANY’S INDEPENDENT AUDITORS FOR THE FISCAL YEAR ENDING DECEMBER 31, 2021, INSTEAD OF BRIGHTMAN ALMAGOR ZOHAR & CO., CERTIFIED PUBLIC ACCOUNTANTS, A FIRM IN THE DELOITTE GLOBAL NETWORK, AND TO AUTHORIZE THE BOARD OF DIRECTORS,
UPON THE RECOMMENDATION OF THE AUDIT COMMITTEE, TO DETERMINE THE AUDITORS’ REMUNERATION TO BE FIXED IN ACCORDANCE WITH THE VOLUME AND NATURE OF THEIR SERVICES TO THE COMPANY FOR SUCH FISCAL YEAR
Background
It is proposed to appoint Kesselman & Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as the Company’s
independent auditors (the “Proposed Auditors”) for the fiscal year ending December 31, 2021, and to end the engagement with Brightman Almagor Zohar & Co., Certified Public Accountants, a firm in the Deloitte Global Network (the “Former
Auditors”), subject to the approval of the Company’s shareholders in the Meeting, and to authorize the Company’s Board of Directors, upon the recommendation of the Audit Committee, to determine the Proposed Auditors’ remuneration to be fixed in
accordance with the volume and nature of their services to the Company for such fiscal year.
It is clarified that, subject to the approval of the Meeting, the Proposed Auditors will review and/or audit, as the case may be, the Company’s financial statements as of the
third quarter of 2021.
The members of the Company’s Audit Committee discussed the replacement of the Company’s Former Auditors, and determined to recommend the replacement of the Former Auditors with
the Proposed Auditors for the following reasons:
|
1.
|
Performing a change of the Company’s independent auditors is desirable from time to time, primarily for reasons of control and efficiency;
|
|
2.
|
The Company’s Audit Committee and Board of Directors were in agreement on the suitability of the Proposed Auditors to conduct an audit of the Company, in light of, inter alia, the nature of the Company’s activities.
|
Proposed Resolution
It is proposed that at the Meeting the following resolution be adopted:
“RESOLVED, that the appointment of Kesselman & Kesselman, certified public accountants in Israel and a member of
PricewaterhouseCoopers International Limited, as the Company’s independent auditors for the fiscal year ending December 31, 2020, instead of Brightman Almagor Zohar & Co., Certified Public Accountants, a firm in the Deloitte Global Network, be,
and the same hereby is, approved, and that the Company’s Board of Directors be, and the same hereby is, authorized, subject to the approval of the Audit Committee, to determine their fees, as presented to the shareholders, be and the same hereby are,
approved.”
Required Vote
Under the Israeli Companies Law and our articles of association, the affirmative vote of the holders of a majority of the ordinary
shares represented at the annual meeting, in person or by proxy, entitled to vote and voting on the matter, is required to re-elect as directors each of the nominees named above.
Board Recommendation
The Board of Directors recommends a vote “FOR” approval of the proposed resolution.
5
PROPOSAL 5:
PROPOSAL TO INCREASE AUTHORIZED SHARE CAPITAL
Background
Our authorized share capital is NIS 5,000,000 divided into 16,666,667 ordinary shares, par value NIS 0.3 each. As of October 26, 2021, 10,482,056 ordinary shares were issued and
outstanding.
The proposal to increase the authorized share capital of the Company is designed to enable us to have sufficient authorized share capital for the upcoming years and in order that
the increase in authorized share capital would allow us to meet our future business needs as they arise. These needs could include, among other things, the sale of shares in public and private offerings to raise additional capital, the purchase of
property or assets, the acquisition of other companies, the use of shares for various equity compensation and other employee benefit plans and arrangements, the declaration of share splits or dividends, and other bona fide corporate purposes.
The possible future issuance of equity securities consisting of ordinary shares or securities convertible into ordinary shares could affect our current shareholders in a number of
ways, including the following: (i) diluting the voting power of the current holders of ordinary shares; (ii) diluting the market price of the ordinary shares, to the extent that the new ordinary shares are issued and sold at prices below current
trading prices of the existing ordinary shares, or if the issuance consists of equity securities convertible into ordinary shares, to the extent that the securities provide for the conversion into ordinary shares at prices that could be below current
trading prices of the ordinary shares; and (iii) diluting the book value per share of the outstanding ordinary shares.
Proposed Resolution
We are proposing adoption by our shareholders of the following resolution at the annual meeting:
“RESOLVED, that the increase to our authorized share capital by NIS 3,000,000, such that following the increase, the authorized share
capital shall equal NIS 8,000,000 divided into 26,666,666 ordinary shares, par value NIS 0.3 each., and the corresponding amendment to our articles of association be, and hereby is, approved in all respects.”
Required Vote
Under the Israeli Companies Law and our articles of association, the affirmative vote of the holders of a majority of the ordinary shares represented at the annual meeting, in person or by proxy,
entitled to vote and voting on the matter, is required for this proposal.
Board Recommendation
The Board of Directors recommends a vote “FOR” approval of the proposed resolution.
6
OTHER BUSINESS
Other than as set forth above, as of the mailing of this proxy statement, management knows of no business to be transacted at the annual meeting, but, if any other matters are
properly presented at the annual meeting, the persons named in the attached form of proxy will vote upon such matters in accordance with their best judgment.
|
|
By Order of the Board of Directors
/s/ Ilan Hadar
Ilan Hadar, Chief Executive Officer
October 27, 2021
|
7
Exhibit 99.2
PainReform Ltd.
PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS
TO BE HELD ON DECEMBER 9, 2021
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS.
The undersigned hereby appoints Mr. Ilan Hadar , Chief Executive Officer, attorney, agent and proxy of the
undersigned, with full power of substitution, to represent and to vote on behalf of the undersigned all the ordinary shares in PainReform Ltd. (the “Company”) which the undersigned is entitled to vote at the Annual General Meeting of Shareholders
(the “Meeting”) to be held at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross., at 7 Metsada st., B.S.R Tower 4, Bnei Brak, Israel, on December 9, 2021 at 11:00 a.m. (Israel time), and at any adjournments
or postponements thereof, upon the following matters, which are more fully described in the Notice of Annual General Meeting of Shareholders (the “Notice”) and Proxy Statement relating to the Meeting (“Proxy Statement”).
The undersigned acknowledges receipt of the Notice of the Annual General Meeting of Shareholders and Proxy
Statement of the Company relating to the Meeting. All terms that are not defined in this Proxy shall have the same meaning of such terms in the Notice and/or the Proxy Statement.
This Proxy, when properly executed, will be voted in the manner directed herein by the undersigned. If no direction
is made with respect to any matter, this Proxy will be voted FOR such matter. Any and all proxies heretofore given by the undersigned are hereby revoked.
(Continued and to be signed on the reverse side)
ANNUAL GENERAL MEETING OF SHAREHOLDERS OF
PAINREFORM LTD.
December 9, 2021, 11:00 a.m. (Israel time)
Please date, sign and mail
your proxy card in the
envelope provided as soon
as possible.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” EACH OF THE PROPOSALS FOR THE MEETING
PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE.
PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE ☒
|
1.
|
To approve the re-election of Prof. Eli Hazum to the Board of Directors, until the next annual general meeting of
shareholders, as detailed in the Proxy Statement dated October 27, 2021.
|
|
|
☐
|
for
|
☐
|
against
|
☐
|
abstain
|
|
2.
|
To approve the re-election of Dr. Ehud Geller to the Board of Directors, until the next annual general meeting of
shareholders, as detailed in the Proxy Statement dated October 27, 2021.
|
|
|
☐
|
for
|
☐
|
against
|
☐
|
abstain
|
|
3.
|
To approve the re-election of Efi Cohen-Arazi to the Board of Directors, until the next annual general meeting of
shareholders, as detailed in the Proxy Statement dated October 27, 2021.
|
|
|
☐
|
for
|
☐
|
against
|
☐
|
abstain
|
|
4.
|
To appoint Kesselman & Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers
International Limited, as the Company’s independent auditors for the fiscal year ending December 31, 2021, instead of Brightman Almagor Zohar & Co., Certified Public Accountants, a firm in the Deloitte Global Network.
|
|
|
☐
|
for
|
☐
|
against
|
☐
|
abstain
|
|
5.
|
To increase the Company’s authorized share capital by NIS 3,000,000, such that following the increase, the authorized share
capital shall equal NIS 8,000,000 divided into 26,666,666 ordinary shares, par value NIS 0.03 each, and to amend the Company’s articles of association accordingly.
|
|
|
☐
|
for
|
☐
|
against
|
☐
|
abstain
|
In their discretion, the proxies are authorized to vote upon such other matters as may properly come before the Meeting or any
adjournment or postponement thereof.
|
|
|
Date: ________, 2021
|
|
|
|
Date_________, 2021
|
|
SIGNATURE
|
|
|
|
SIGNATURE
|
|
|
Please sign exactly as your name appears on this Proxy. When shares are held jointly, each holder should sign. When signing as
executor, administrator, trustee or guardian, please give full title as such. If the signed is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in
partnership name by authorized person.
2